Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cipher Reports Strong Q2 2012 Financial Results


      News provided by

      Cipher Pharmaceuticals Inc.

      Jul 25, 2012, 07:00 ET

      Share this article

      Share this article


      - Results highlighted by solid revenue growth and FDA approval of CIP-ISOTRETINOIN -

      Toronto Stock Exchange Symbol: DND

      MISSISSAUGA, ON, July 25, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF) today announced its financial and operational results for the three and six months ended June 30, 2012 ("Q2 2012").

      Q2 2012 Summary

      • Achieved quarterly net revenue of $1.6 million, a 124% increase over Q2 2011.
      • Net income in Q2 2012 was $0.2 million, compared with a loss of $0.5 million in Q2 2011.
      • Achieved final FDA approval of CIP-ISOTRETINOIN; product to be launched by the Company's U.S. partner Ranbaxy in Q4 2012 as Absorica™.
      • Received a US$4.5 million net milestone for final FDA approval of CIP-ISOTRETINOIN.
      • Cash balance increased strongly to $14.4 million, compared with $10.1 million as at March 31, 2012.

      "It was an excellent quarter for the Company both financially and from a product development perspective, highlighted by final FDA approval of our high-potential acne product, Absorica™," said Larry Andrews, President and CEO of Cipher. "Revenue from Lipofen® was solid and we had early contributions from our once-daily tramadol product which is now marketed both in the U.S. and Canada as ConZip® and Durela™. With the pending launch of Absorica™ in Q4 of this year, we will have three product revenue streams, no debt and a strong cash position to fund future growth opportunities."

      Financial Review

      Net revenue in Q2 2012 was $1.6 million, an increase of 124% compared with $0.7 million in Q2 2011. Net revenue from Lipofen® increased to $0.9 million during Q2 2012, compared with $0.6 million in Q2 2011. Net revenue from ConZip® was $0.4 million in Q2 2012.  No revenue was recognized in Q2 of the prior year as the product was launched in Q3 2011. Revenue from Durela™ was not significant during Q2 2012 as the product was only launched in mid-March 2012. Absorica™ contributed $0.3 million of net revenue reflecting recognition of milestones received to date.

      Research and Development expense decreased during Q2 2012 to $0.3 million, compared with $0.6 million in Q2 2011. Operating, General and Administrative expenses for Q2 2012 were $0.9 million, compared to $0.6 million in Q2 2011. Net income in Q2 2012 was $0.2 million, or $0.01 per share, compared with a net loss of $0.5 million, or $0.02 per share, in Q2 2011.

      The Company's financial position remained strong at quarter end. As at June 30, 2012, Cipher had cash and cash equivalents of $14.4 million, compared with $10.1 million as at March 31, 2012. During Q2 2012, the Company received a $4.5 million milestone payment (net of the amount shared with its partner) for final FDA approval of CIP-ISOTRETINOIN.

      Product Update

      Lipofen®
      During Q2 2012, Kowa's solid promotional effort resulted in Lipofen® monthly prescriptions and sales increasing significantly as reflected in a 50% increase in the Cipher's net revenue over Q2 2011. Subsequent to quarter end, Cipher achieved another contractual sales goal for the product and as a result, the royalty percentage for Lipofen® increases by three percentage points on a go-forward basis.  This change is retroactive to October 2011 and will result in a one-time "catch-up" payment to Cipher, which will be recorded in Q3 2012.

      CIP-TRAMADOL ER (ConZip®/Durela™)
      Cipher's extended-release tramadol was launched in the U.S. by Vertical Pharmaceuticals in September 2011 under the trade name ConZip®. Vertical's dedicated sales force comprises 60 representatives, with plans for further expansion in Q4 2012. Product sales have increased steadily during 2012 and the Company expects continued growth as U.S. physicians gain more experience with the product and Vertical expands its coverage.

      In Canada, Medical Futures launched the product in March 2012 under the trade name Durela™, with a dedicated sales force comprising 22 representatives.

      CIP-ISOTRETINOIN (Absorica™)
      During Q2 2012, Cipher achieved a major milestone with final FDA approval of CIP-ISOTRETINOIN for the treatment of severe recalcitrant nodular acne. The product will be launched in the U.S. market under the name Absorica™ and pre-commercial activities are underway with the Company's partner, Ranbaxy Pharmaceuticals, for a planned U.S. launch in Q4 2012.  As a result of the FDA approval of Absorica™, Cipher received a US$9.0 million milestone from Ranbaxy, approximately 50% of which was shared with Galephar. Going forward, Cipher will also receive royalties on net U.S. sales and is eligible for future milestone payments based on sales targets. Under the agreement with Ranbaxy, Cipher is responsible for product supply and manufacturing.

      Cipher completed a New Drug Submission to Health Canada in Q4 2011.  This has been accepted for review, with a response from Health Canada expected by Q1 2013.  Once approved, the Company plans to market the product in Canada on its own.

      New Products and Out-Licensing Activities
      Cipher is actively pursuing out-licensing discussions for its current products in other territories and is seeking late-stage to commercial-stage product candidates to complement its Canadian commercialization plans for CIP-ISOTRETINOIN.

      Notice of Conference Call

      Cipher will hold a conference call today, July 25, 2012, at 8:30 a.m (ET) to discuss its financial results and other corporate developments. To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191.  A live audio webcast of the call will be available at www.cipherpharma.com. The webcast will be archived for 90 days.

      About Cipher Pharmaceuticals Inc.

      Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules.  Cipher's strategy is to in-license clearly differentiated products, advance them through the clinical development and regulatory approval stages, and out-license to international marketing partners.  The Company's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip® and is marketed in Canada as Durela™.  Cipher's third product, a novel formulation of the acne treatment isotretinoin, was recently approved by the FDA and is expected to be launched in Q4 2012 as Absorica™.  The product is also currently being reviewed by Health Canada. For more information, please visit www.cipherpharma.com.

      Forward-Looking Statements

      Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements.  Factors that could cause results to vary include those identified in the Company's Annual Information Form and other filings with Canadian securities regulatory authorities. These factors include, but are not limited to losses; the applicability of patents and proprietary technology; possible patent litigation; approval of products in the Company's pipeline; marketing of products; meeting projected drug development timelines and goals; product liability and insurance; dependence on strategic partnerships and licensees; concentration of the Company's revenue; substantial competition and rapid technological change in the pharmaceutical industry; the publication of negative results of clinical trials of the Company's products; the ability to access capital; the ability to attract and retain key personnel; changes in government regulation or regulatory approval processes; dependence on contract research organizations; third party reimbursement; the success of the Company's strategic investments; the achievement of development goals and time frames; the possibility of shareholder dilution; market price volatility of securities; and the existence of significant shareholders. All forward-looking statements presented herein should be considered in conjunction with such filings. Except as required by Canadian securities laws, the Company does not undertake to update any forward-looking statements; such statements speak only as of the date made.

      Cipher Pharmaceuticals Inc.

      Financial Statements

      For the Six Months Ended June 30, 2012
      (Unaudited)

      Cipher Pharmaceuticals Inc.                              
      Balance Sheets                              
                                     
      As at June 30, 2012 and December 31, 2011                              
      (in thousands of Canadian dollars - unaudited)                              
                                     
                                     
                      June 30,       December 31,
                      2012       2011
                      $       $
      ASSETS                              
                                     
      Current assets                              
        Cash and cash equivalents                     14,403       9,636
        Accounts receivable                     2,340       1,782
        Prepaid expenses and other assets                     75       272
                            16,818       11,690
                                     
        Property and equipment, net                     24       25
                                     
        Intangible assets, net                     3,145       2,944
                                     
                            19,987       14,659
                                     
      LIABILITIES                              
                                     
      Current liabilities                              
        Accounts payable and accrued liabilities                     2,015       1,912
        Current portion of deferred revenue                     2,409       917
                            4,424       2,829
                                     
        Deferred revenue                     5,554       2,330
                            9,978       5,159
                                     
      SHAREHOLDERS' EQUITY                              
                                     
        Share capital                     50,254       50,172
        Contributed surplus                     33,124       33,032
        Deficit                     (73,369)       (73,704)
                            10,009       9,500
                                     
                            19,987       14,659
                                     
                                     
                                     
      Cipher Pharmaceuticals Inc.                    
      Statements of Operations and Comprehensive Income (Loss)          
                           
      Three and six month periods ended June 30, 2012 and 2011          
      (in thousands of Canadian dollars, except per share data - unaudited)        
                           
                           
              Three months   Six months
              June 30,   June 30,   June 30,   June 30,
              2012   2011   2012   2011
              $   $   $   $
                           
      Revenues                    
        Licensing revenue       1,629   727   3,440   1,402
                           
      Expenses                    
        Research and development       348   578   819   1,125
        Operating, general and administrative       861   618   1,877   1,795
        Amortization of intangible assets       245   60   470   119
        Interest income       (35)   (20)   (61)   (43)
                           
              1,419   1,236   3,105   2,996
                           
      Income (loss) before income taxes       210   (509)   335   (1,594)
                           
      Provision for (recovery of) income taxes                    
        Current       127   -   127   -
        Deferred       (127)   -   (127)   -
                           
      Income (loss) and comprehensive income (loss)
      for the period
            210   (509)   335   (1,594)
                           
                           
      Basic and diluted earnings (loss) per share       0.01   (0.02)   0.01   (0.07)
      Cipher Pharmaceuticals Inc.                            
      Statements of Changes in Equity                            
                                   
      Six month periods ended June 30, 2012 and 2011                            
      (in thousands of Canadian dollars - unaudited)                            
                                   
                                   
                                  Total
              Share     Contributed             Shareholders'
              Capital     Surplus       Deficit     Equity
              $     $       $     $
                                   
      Balance, January 1, 2012       50,172     33,032       (73,704)     9,500
                                   
      Income and comprehensive income for the period       -     -       335     335
                                   
      Exercise of stock options       8     (8)       -     -
                                   
      Shares issued under the share purchase plan       74     -       -     74
                                   
      Share-based compensation - stock option plan       -     100       -     100
                                   
      Balance, June 30, 2012       50,254     33,124       (73,369)     10,009
                                   
                                   
      Balance, January 1, 2011       49,977     32,890       (71,393)     11,474
                                   
      Loss and comprehensive loss for the period       -     -       (1,594)     (1,594)
                                   
      Exercise of stock options       90     (43)       -     47
                                   
      Share-based compensation - stock option plan       -     81       -     81
                                   
      Balance, June 30, 2011       50,067     32,928       (72,987)     10,008
                                 
                                 
                               
      Cipher Pharmaceuticals Inc.              
      Statements of Cash Flows              
                     
      Three and six month periods ended June 30, 2012 and 2011              
      (in thousands of Canadian dollars - unaudited)              
                     
                     
        Three months   Six months
        June 30,   June 30,   June 30,   June 30,
        2012   2011   2012   2011
        $   $   $   $
                     
      Cash provided by (used in)              
                     
      Operating activities              
        Income (loss) for the period 210   (509)   335   (1,594)
        Items not affecting cash:              
          Depreciation of property and equipment 6   8   13   21
          Amortization of intangible assets 245   60   470   119
          Share-based compensation - share purchase plan 5   -   11   -
          Share-based compensation - stock option plan 51   53   100   81
        517   (388)   929   (1,373)
                     
        Changes in non-cash operating items:              
          Accounts receivable (403)   (238)   (558)   (22)
          Prepaid expenses and other assets 105   158   197   258
          Accounts payable and accrued liabilities (197)   (247)   103   (611)
          Deferred revenue 4,911   96   4,716   (48)
                     
      Net cash generated from (used in) operating activities  4,933   (619)   5,387   (1,796)
                     
      Investing activities              
        Purchase of property and equipment (2)   (2)   (12)   (6)
        Acquisition of intangible rights (671)   -   (671)   -
                     
      Net cash generated from (used in) investing activities  (673)   (2)   (683)   (6)
                     
      Financing activities              
        Proceeds from shares issued under the share purchase plan 30   -   63   -
        Proceeds from exercise of stock options -   47   -   47
                     
      Net cash generated from (used in) financing activities  30   47   63   47
                     
                     
      Increase (Decrease) in cash and cash equivalents 4,290   (574)   4,767   (1,755)
      Cash and cash equivalents, beginning of period 10,113   9,147   9,636   10,328
                     
      Cash and cash equivalents, end of period 14,403   8,573   14,403   8,573

      SOURCE: Cipher Pharmaceuticals Inc.

      Craig Armitage
      Investor Relations
      The Equicom Group
      (416) 815-0700 ext 278
      (416) 815-0080 fax
      [email protected]

      Larry Andrews
      President and CEO
      Cipher Pharmaceuticals
      (905) 602-5840 ext 324
      (905) 602-0628 fax
      [email protected]

      Modal title

      Organization Profile

      Cipher Pharmaceuticals Inc.

        Also from this source

      • Cipher Pharmaceuticals Reports Third Quarter 2026 Results

      • Cipher Pharmaceuticals Schedules Q3 2026 Earnings Release and Conference Call

      • Cipher Pharmaceuticals Announces the Appointment of Rajiv De Silva to its Board of Directors

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.